Delivery Order SPE2DB22D1052-SPE2DB25FU8LV

Award Date 2/5/25
Potential Completion Date 2/6/25
Potential Value $5.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $3,011.02 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,560,832,406 units of Naloxone HCL 4 mg nasal spray. This delivery order contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the procurement of 4,560,715,310 units of Naloxone HCl 4 mg Nasal Spray. The delivery order, valued at $3,008.61, has a firm fixed price and will be completed by April 26, 2023. This contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,562,868,958 units of NALOXONE HCL 4 MG NASAL SPRAY 2S, with a ceiling value of $3,135.20 and a period of performance through November 21, 2023. The contract is a firm fixed-price delivery order and does not have a set-aside designation. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,559,464,440 units of 4 mg Naloxone HCl nasal spray, a critical medication used to treat opioid overdoses. The contract has a ceiling value of $2,737.24 and an ultimate completion date of December 29, 2022. This award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award is a firm fixed price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The contract is for the supply of 4,563,955,933 units of Naloxone HCl 4 mg Nasal Spray in 2-count packages, with a total ceiling value of $5,637.45 and an ultimate completion date of March 14, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,542.26 firm fixed-price delivery order is for the supply of 4,566,382,872 units of Naloxone HCl 4 mg Nasal Spray. The contract has an ultimate completion date of November 12, 2024 and was awarded on November 8, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This federal contract award is for the delivery of 4,559,406,389 units of Naloxone HCl 4 mg Nasal Spray to the Defense Logistics Agency (DLA). The award, valued at $3,854.16, was made to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a period of performance through December 19, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,559,450,602 units of Naloxone HCL 4 mg Nasal Spray. The contract is a Delivery Order with a Firm Fixed Price of $1,855.43 and a completion date of December 27, 2022. The contract was not set aside for any specific business category. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a $1,262.40 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract provides 4,567,065,647 units of NALOXONE HCL 4 MG NASAL SPRAY 2S, with a completion date of January 29, 2025. This delivery order is placed under an existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,369.72 fixed-price delivery order is for the supply of 4,566,326,707 units of Naloxone HCL 4 mg Nasal Spray, with a completion date of November 5, 2024. The contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as...
  • SPE2DB22D1052
    Indefinite Delivery Contract
  • SPE2DB22D1052-SPE2DB25FU8LV
    Delivery Order

This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,778.75, is for the delivery of 4,567,175,312 units of Naloxone HCL 4 mg Nasal Spray. The delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/7/25, 9:56 AM